Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...
Socioeconomic and demographic factors impact surgical outcomes in upper extremity soft tissue sarcomas, affecting amputation ...
The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results